ReviewCureus2026
A Systematic Review Showing the Comparative Efficacy and Safety of Endoscopic Submucosal Dissection Versus Endoscopic Mucosal Resection in the Management of Colorectal Neoplasia.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal neoplasia contributes substantially to the global burden of disease, and selecting the most appropriate endoscopic treatment is essential to reduce recurrence and avoid surgery. This systematic review focused exclusively on direct comparisons of endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) for colorectal neoplasia while excluding non-colorectal lesions, single-arm studies, rectal neuroendocrine tumors, and other non-comparable interventions (studies without direct EMR versus ESD comparison). A systematic search of PubMed, Embase, and Scopus from inception to June 2025 was performed in accordance with the PRISMA guidelines. Six reviewers independently screened studies, and 17 comparative studies involving 3790 lesions were included. Data were extracted for tumor size, procedure time, en bloc resection, complete RO resection, recurrence, and major complications, including perforation and delayed bleeding. Risk of bias was assessed using the Newcastle-Ottawa Scale for observational studies and the Cochrane Risk of Bias 2 (RoB 2) tool for randomized trials. Across included studies, ESD was used for larger lesions, required longer procedure times, and achieved higher en bloc and R0 resection rates than EMR. ESD also demonstrated lower recurrence, whereas perforation and delayed bleeding were generally more frequent after ESD. EMR remained faster and was associated with a lower perforation risk, particularly in smaller and less complex lesions. Overall, ESD provides superior oncologic resection quality and lower recurrence but at the cost of greater technical burden and a higher complication profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.